Clinical stage cell and gene therapy company Elicera Therapeutics AB (publ) announced on Thursday that it has completed patient enrolment in its phase I/II trial for the oncolytic drug candidate ELC-100 (AdVince) targeting neuroendocrine tumours.

Sponsored by Uppsala University, the study consists of a dose escalation phase and a dose expansion phase. The current dose escalation phase aims to determine safety and the maximum tolerated dose (MTD) while assessing tumour response. 12 patients have been enrolled, with treatment now initiated for the final participant.

ELC-100 selectively targets and destroys neuroendocrine cancer cells without harming healthy cells. VictoryNET-Foundation fully funds the clinical study. Based on study outcomes and regulatory discussions, Elicera will define its future development strategy for ELC-100. Preliminary results are expected in the first half of 2025.